MORRISVILLE, N.C.--(BUSINESS WIRE)--etrials® Worldwide, Inc. (Nasdaq: ETWC, ETWCW, ETWCU), a leading provider of eClinical software and services that optimize clinical-trial management and accelerate time-to-market, today announced that the Securities and Exchange Commission (SEC) declared effective its post-effective amendment on Form S-3. The post-effective amendment updates its prior registration statements on Form S-1 and Form S-4 to allow etrials to honor exercises of up to 13 million common stock purchase warrants, which trade on NASDAQ under the symbol ETWCW. Future warrant exercises, and issuances of common stock upon exercise, are subject to etrials maintaining the effectiveness of its registration statement until the warrants expire on February 12, 2008.
